Medicine Advances最新文献

{"title":"Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention","authors":"Yi-Long Wu, Shun Lu, Ying Cheng, Qing Zhou, H. Tu, Qing Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, S. Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, Anwen Liu, Xu‐Chao Zhang, Hui Li, Rong-rong Chen, Dong‐Mei Lin, Congying Xie, Zheng‐Fei Zhu, Hui-Ying Liang, Yong Song, Xiaorong Dong, Ming‐Fang Zhao, Gui-Bin Qiao, J. Cui, Ziming Li, Zhijie Wang, Xiao-Yuan Chen, N. Yang, G. Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, J. Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Q-T Yu, Li‐Feng Wang, Hai-bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui-juan Wang, Fang Wu, Wenzhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Li Zhang, Fan Yang, Qun Wang, Dongsheng Yue, Jianying Zhou, Peng Shen, Jia‐Tao Zhang, XiaoLan Yan, Meijuan Huang, Wei Feng, Li Li","doi":"10.1002/med4.44","DOIUrl":"https://doi.org/10.1002/med4.44","url":null,"abstract":"The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challenge for diagnosis and therapeutic targeting. In the never‐smokers/low smokers category with mutations such as EGFR and HER2, the efficacy of immune checkpoint inhibitors (ICIs) remains suboptimal, attributed to lower PD‐L1 expression and tumor mutation burden (TMB). However, heavy smokers, often with mutations like KRAS, may derive benefits from ICIs, as supported by trials like CheckMate‐057. With the complex landscape of these drivers and their clinical implications, the summit culminated in six pivotal consensus points, aiming to guide future research and clinical decisions. Despite the advancements, the detection, interpretation, and therapeutic strategies involving these drivers necessitate further exploration and standardization.","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139009234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic pancreatic cancer mimicking medication related osteonecrosis of the jaw—A rare clinical presentation","authors":"Sandeep Gurav, Gurkaran Preet Singh, V. Ostwal, Madhura R. Sharma, Kiran Jagtiani","doi":"10.1002/med4.42","DOIUrl":"https://doi.org/10.1002/med4.42","url":null,"abstract":"Pancreatic cancer is a highly aggressive malignancy with a poor prognosis owing to its rapid progression, high mortality rate, and alarming 5‐year survival rate of 5%. Skeletal metastases represent an understated site of metastasis in patients with pancreatic cancer, occurring in about 5%–20% of these patients. The clinical presentation of metastasis to the jaws and osteonecrosis of jaw can exhibit similarities, which may lead to an erroneous diagnosis or create a diagnostic dilemma. We present a case of a 62‐year‐old male patient diagnosed with pancreatic adenocarcinoma and a prior history of bisphosphonate administration who displayed symptoms such as jaw pain, numbness, reduced mouth opening, and an extra‐oral swelling involving a recent tooth extraction site, likely due to medication‐related osteonecrosis of the jaw (ONJ). Despite initial conservative treatment, the patient's symptoms persisted, prompting further investigation. Depending on the specific context and clinical scenario, it is crucial to employ a comprehensive approach such as clinical examination, radiographic imaging, histopathological examination and monitoring the progression of symptoms over time for accurate diagnosis and timely management. This article presents a rare case of metastatic pancreatic cancer mimicking medication related ONJ, highlighting the clinical dilemma and challenges encountered when presenting symptoms and signs are ambiguous. While the prognosis for such cases is generally poor, dentists and healthcare providers should remain vigilant regarding potential sites of metastasis in cases of pancreatic adenocarcinoma.","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138592847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystic acne treatment: A comprehensive review","authors":"Akiladevi Durairaj, Karthikeyan Elumalai, Anandakumar Shanmugam","doi":"10.1002/med4.43","DOIUrl":"https://doi.org/10.1002/med4.43","url":null,"abstract":"Acne, a common skin condition, is primarily seen in teenagers and young adults and is characterised by large pus‐filled bumps beneath the skin. Cystic acne is a common form and is linked to a high incidence of acne‐related skin diseases. Causes include age, sex, and lifestyle changes. Treatment options for severe acne include medications, laser therapy, chemical peels, and microneedling patches. This review focuses on cystic acne treatment options and discusses their advantages and disadvantages. Medications like isotretinoin reduce inflammation but have side effects. Laser therapy targets bacteria without medication but may require multiple sessions for optimal results.","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138597656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and development of a multi‐epitope vaccine for the prevention of latent tuberculosis infection","authors":"Fan Jiang, Lingling Wang, Jie Wang, Peng Cheng, Jing Shen, Wenping Gong","doi":"10.1002/med4.40","DOIUrl":"https://doi.org/10.1002/med4.40","url":null,"abstract":"Abstract Background Latent tuberculosis infection (LTBI) often progresses to active tuberculosis, necessitating the development of novel vaccine to prevent LTBI. In this study, we aimed to design a Mycobacterium tuberculosis ( M. tuberculosis ) vaccine that could elicit a potent immune response to prevent LTBI. Methods We used bioinformatics and immunoinformatics techniques to develop a multi‐epitope vaccine (MEV) called C624P. The vaccine contained six cytotoxic T lymphocytes (CTL), two helper T lymphocytes (HTL), and four B‐cell epitopes derived from six antigens associated with LTBI and the Mycobacterium tuberculosis region of difference. We added Toll‐like receptor (TLR) agonists and PADRE peptide to the MEV to enhance its immunogenicity. We then analyzed the C624P vaccine's physical and chemical properties, spatial structure, molecular docking with TLRs, and immunological features. Results The C624P vaccine displayed good antigenicity and immunogenicity scores of 0.901398 and 3.65609, respectively. The vaccine structure was stable, with 42.82% α‐helix content, a Z‐value of −7.84, and a favored Ramachandran plot area of 85.84% after majorization. Molecular docking analysis showed that the C624P vaccine could bind tightly to TLR2 (−1011.0 kcal/mol) and TLR4 (−941.4 kcal/mol). Furthermore, the C624P vaccine effectively stimulated T and B lymphocytes, resulting in high levels of Th1 cytokines such as IFN‐γ and IL‐2. Conclusions The C624P vaccine represents a promising MEV for preventing LTBI. The vaccine's good antigenicity, immunogenicity, stability, and ability to activate immune responses suggest its effectiveness in preventing LTBI. Our study demonstrated the utility of bioinformatics and immunoinformatics techniques in designing safe and effective tuberculosis vaccines.","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134954638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of dietary patterns with cognitive function in older people: Results from the Chinese longitudinal healthy longevity survey","authors":"Haiqing Zheng,&nbsp;Huixian Li,&nbsp;Lingcong Kong,&nbsp;Xueli Zhang,&nbsp;Yunfei Gao,&nbsp;Lianting Hu,&nbsp;Xianwen Shang,&nbsp;Huiying Liang","doi":"10.1002/med4.35","DOIUrl":"https://doi.org/10.1002/med4.35","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dietary patterns are crucial for maintaining cognitive health among older people and can be modified through lifestyle interventions. We investigated the associations between dietary patterns, changes in these patterns over time, and cognitive function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cohort study utilized data from the Chinese Longitudinal Healthy Longevity Survey conducted between 2005 and 2014. The sample included 7472 participants (mean age: 81.45 ± 10.88 years). Dietary patterns were derived using cluster analysis. Cognitive function was assessed using the Mini-Mental State Examination (MMSE). The relationships between dietary patterns/changes, MMSE scores, changes in MMSE scores, and cognitive impairment were analyzed using the generalized estimating equation method, linear regression, and logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cluster analysis identified three major dietary patterns: balanced diet, relatively balanced diet, and unbalanced diet. Mean MMSE scores decreased from 24.71 ± 7.24 in 2005 to 22.22 ± 9.29 in 2008, then increased to 24.10 ± 7.76 in 2014. Participants who adhered to balanced diet patterns exhibited significantly higher MMSE scores (1.56; 95% confidence interval: 1.34, 1.78) than those who followed unbalanced diet patterns. This association was particularly prominent among older individuals, women, individuals with no education, and underweight individuals. Participants with relatively balanced or balanced diets showed a significantly lower risk of cognitive impairment (adjusted odds ratio (OR) = 0.72, 95% CI: 0.65, 0.80; OR = 0.47, 95% CI: 0.42, 0.53, respectively) than those with unbalanced diets. Transitioning from an unhealthy diet to a healthy diet was associated with a smaller decline in MMSE scores and reduced risk of cognitive impairment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings emphasize the importance of balanced or relatively balanced diets in preserving cognitive health in older individuals. These patterns relate to better MMSE scores and reduced cognitive impairment risk. Shifting from unhealthy to healthy diets is linked to improved MMSE scores and lower cognitive impairment risk. These results underscore the importance of dietary interventions in mitigating cognitive decline in older adults. Further research is warranted to understand the underlying mechanisms and develop targeted strategies for promoting healthy dietary habits in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50154765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncovering the heterogeneity and cell fate decisions of endothelial cells after myocardial infarction by single-cell sequencing","authors":"Xinyang Long,&nbsp;Boteng Yan,&nbsp;Zengnan Mo","doi":"10.1002/med4.34","DOIUrl":"https://doi.org/10.1002/med4.34","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The plasticity of endothelial cells (ECs) is crucial for tissue response to injury. Myocardial infarction can profoundly affect EC function, leading to a shift toward mesenchymal differentiation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We utilized human single-nucleus RNA sequencing data to investigate the dynamic changes and cellular interactions between normal and post-infarction ECs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified two distinct subpopulations of ECs: A transient subpopulation characterized by short-term mesenchymal gene expression and a long-term subpopulation characterized by myocardial gene expression. Trajectory analysis revealed the differentiation pathways and potential roles over time and space. Furthermore, we uncovered the proliferation, differentiation, hypoxic, and inflammatory responses of ECs to injury.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study provides a comprehensive and detailed characterization of endothelial cell states, highlighting the role of activated endothelial cell subpopulations in promoting inflammation and tissue repair after infarction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.34","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50154767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel nanomaterials as photo-activated cancer diagnostics and therapy","authors":"Deepika Yadav,&nbsp;Rishabha Malviya","doi":"10.1002/med4.36","DOIUrl":"https://doi.org/10.1002/med4.36","url":null,"abstract":"<p>The word “theranostics” describes an emerging trend in medicine in which the distinction between diagnosis and therapy blurs. Light or photo is used in theranostics to obtain high precision and personalised treatment. As only malignant tissues need to be spared, photo-triggered theranostics provide highly selective targeting using real-time imaging. Using nanotechnology to organise a dual-modality approach is an efficient way to circumvent pharmacokinetic limitations. Photodynamic therapy has been used successfully in the clinic for a while now, and this has paved the path for photo-triggered theranostics to be developed. The use of light-activated theranostic nanoforms has progressed from preclinical studies in animals and labs to clinical trials in humans. As both nanomaterials and their methods of manufacture advance, the theranostic approach becomes more nuanced and may be used in a wider range of real-time imaging and therapy modalities. The depth of anatomical access is also expanding because of developments in light delivery technologies. Combined, these innovations will hasten early cancer diagnosis and make tailored treatment more feasible. A non-invasive assessment approach also increases patient compliance and reduces risk. Researchers constantly make strides in their effort to create more versatile photo-sensitive nanoparticles. With any luck, photo-triggered theranostics may significantly reduce toxicity. In order to provide a better and safer clinical outcome in cancer therapy, this review aims to highlight the latest and greatest innovation research in the domain of nanotheranostics and its photo-triggering, and to sketch the possibilities for further progression and integration of nanoconstructs and photo-delivery, and trying to target approach in photo-triggered theranostics.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.36","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50153806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical management algorithms for late complications after colorectal and anal cancer—Basic treatment of late complications","authors":"Birthe Thing Oggesen,&nbsp;Marie Louise Sjødin Hamberg,&nbsp;Jacob Rosenberg","doi":"10.1002/med4.32","DOIUrl":"https://doi.org/10.1002/med4.32","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The aim of this work was to develop a basic treatment guideline set for late complications after treatment for colorectal and anal cancer. Furthermore, a prerequisite was that the guideline was appropriate and safe to use for all health care staff regardless of their educational level. Lastly, the set should cover the most common late complications for patients treated for colorectal and anal cancer, including stool, urinary, sexual, and depressive symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The treatment algorithms were developed by doctors in the Late Complication Clinic and afterward they were discussed to establish consensus with external experts in different fields such as surgery, gastroenterology, dietitian, gynecology, urology, sexology, general practice, anesthesiology, and psychiatry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We have developed a practical basic guideline set covering the most common late complications after colorectal and anal cancer treatment. The guideline set can be used by both nurses and doctors. The treatment algorithms are a combination of ordinary treatment principles and the best possible evidence in the field of late complications after colorectal and anal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We have developed a basic treatment guideline set for late complications after treatment for colorectal and anal cancers. There is generally little evidence in the field of late complications, and the evidence is mostly based on consensus. To establish higher-level evidence for late complication treatment after colorectal and anal cancer, it is important to monitor and adjust the treatment algorithms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.32","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50138399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of the use of Ofatumumab in the treatment of relapsing-remitting multiple sclerosis","authors":"Peter Olujimi Odutola,&nbsp;Peter Oluwatobi Olorunyomi,&nbsp;Olanrewaju Olamide Olatawura,&nbsp;Ifeoluwapo Olorunyomi,&nbsp;Olukayode Oluyinka Madojutimi,&nbsp;Uju Okeke,&nbsp;Ayomide O. Fatunsin,&nbsp;Victoria Eneh","doi":"10.1002/med4.33","DOIUrl":"https://doi.org/10.1002/med4.33","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ofatumumab is the first monoclonal antibody developed specifically for treating relapsed multiple sclerosis (RMS). This disease (Multiple Sclerosis) includes relapsing–remitting multiple sclerosis (RRMS), a chronic autoimmune illness that affects the central nervous system (CNS), including the brain and spinal cord. The purpose of this study is to determine whether Ofatumumab is efficacious and safe in the treatment of relapsing–remitting multiple sclerosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An analysis of studies comparing Ofatumumab with placebo in people with relapsing-remitting multiple sclerosis was done in accordance with PRISMA guidelines. We looked up information in MEDLINE, SciSearch, BIOSIS Previews, Derwent Drug File, Embase, and International Pharmaceutical Abstracts. In patients with relapsing–remitting multiple sclerosis, randomized double-blind and non-randomized trials contrasting Ofatumumab with placebo were found by two independent investigators. Utilizing Review Manager 5.4.1, data were examined. The main results were total gadolinium-enhancing (Gd+) T1 lesions, annualized relapse rate, and new or expanding total T2 lesions. Secondary outcomes concentrated on general adverse events and adverse events related to infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three studies were included involving 334 patients, and the meta-analysis indicated that Ofatumumab showed good efficacy and safety in patients with relapsing forms of multiple sclerosis. The annual rate of relapse was significantly reduced by Ofatumumab (OR 0.51; 95% CI 0.27, 0.98; <i>P</i> = 0.04). Ofatumumab reduced the number of gadolinium-enhancing (Gd+) T1 lesions per scan (Mean difference −0.59; 95% CI −0.63, −0.55; <i>P</i> &lt; 0.05). Ofatumumab treatment decreased new or enlarging total T2 lesions significantly (Mean difference −1.03; 95% CI −1.29, −0.76; <i>P</i> &lt; 0.05). Infection-related adverse effects were seen more frequently with Ofatumumab shown by the odd ratio 0.48; 95% CI 0.22, 1.04; <i>P</i> = 0.06. Infection is, thus, a major limitation to its use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The meta-analysis indicated that Ofatumumab is efficacious and safe for patients with relapsing forms of multiple sclerosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.33","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50132933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of potential key ferroptosis genes in the pathogenesis of ankylosing spondylitis by bioinformatics","authors":"Guoxian He,&nbsp;Zexin Chen,&nbsp;Jiaxiao Li,&nbsp;Lanhui Zhang,&nbsp;Suling Liu,&nbsp;Yang Cui","doi":"10.1002/med4.31","DOIUrl":"https://doi.org/10.1002/med4.31","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ankylosing spondylitis (AS) is a disabling chronic inflammatory disease. Mechanisms of ferroptosis in AS remain unclear. Using bioinformatics analysis, we aimed to identify key molecules involved in ferroptosis, provide potential therapeutic targets for AS, and further explore mechanisms of ferroptosis in AS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>GSE25101 was downloaded from the Gene Expression Omnibus and intersected with a ferroptosis gene dataset. The ferroptosis-relate differentially-expressed genes were further subjected to functional enrichment analysis, protein interaction network analysis, and gene-miRNA interaction network analysis, from which potential key ferroptosis genes in the pathogenesis of ankylosing spondylitis were screened.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 20 differentially expressed genes were screened, most of which are involved in phosphoinositide 3 kinase-Akt or mitogen-activated protein kinase (MAPK) signaling pathways or the endoplasmic reticulum stress response. The following target genes were identified through protein-protein interaction network analysis and screening of key modules constructed from genes associated with PI3K-Akt and MAPK signaling pathways: TP53, PTEN, TLR4, HSPB1, DDIT3, and XBP1. In addition, PI3K-Akt and MAPK signaling were associated with oxidative stress, which may play a role in AS pathological ossification related to ferroptosis. Only hsa-miR-205-5p was found to target at least two genes by gene-miRNA interaction network analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Future therapeutic drug development may intervene by modulating MAPK or PI3K-Akt signaling pathways rather than directly affecting the interleukin 17 pathway. hsa-miR-205-5p may be a potential novel biomarker for AS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50132934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}